Mersana Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Collaboration revenue
Operating expenses:
Research and development expense:
General and administrative expense
Restructuring expenses
Total operating expenses
Other income (expense):
Interest income
Interest expense
Total other income (expense), net
Loss before income taxes
Income tax expense
Net loss
Other comprehensive loss:
Unrealized (loss) gain on marketable securities
Comprehensive loss
Net loss attributable to common stockholders - basic
Net loss attributable to common stockholders - diluted
Net loss per share attributable to common stockholders — basic and diluted (in dollars per share)
Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted (in shares)
Net loss per share attributable to common stockholders — basic (in dollars per share)
Net loss per share attributable to common stockholders — diluted (in dollars per share)
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares)
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares)

Comments